MICOS13

Across TCGA pan-cancer cohorts, MICOS13 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MICOS13’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MICOS13 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MICOS13 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

LIHC, KIRC, and COAD are the cancer types where MICOS13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MICOS13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+1.010	<.001	8	view →
KIRC	Male	III,IV	+0.455	<.001	8	view →
COAD	Female	II,III,IV	+0.629	<.001	7	view →
KIRP	Female	II,III,IV	+0.581	.002	4	view →
CHOL	All	All	+1.327	<.001	3	view →
BRCA	All	IV	−0.435	.001	2	view →
ESCA	All	All	+0.530	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MICOS13–LIHC

Open the LIHC breakdown →